BCM
CORT icon

BlueCrest Capital Management’s Corcept Therapeutics CORT Stock Holding History

BlueCrest Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-12,661
Closed -$69K – 779
2016
Q2 		$69K Buy
+12,661
New +$65.9K ﹤0.01% 829

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BlueCrest Capital Management's CORT Position: Q3 2016 in Review

BlueCrest Capital Management sold out of Corcept Therapeutics (CORT) in Q3 2016, closing a stake of 12,661 shares — an estimated $69K sold.

BlueCrest Capital Management first reported a position in CORT in Q2 2016 and held it in 1 quarter. The position peaked at $69K in Q2 2016. 110 funds tracked by Wall St. Rank hold CORT as of Q3 2016.

  • BlueCrest Capital Management reported no remaining Corcept Therapeutics position as of Q3 2016 after selling out during the quarter.
  • BlueCrest Capital Management sold 12,661 Corcept Therapeutics shares in Q3 2016, an estimated $69K.
  • BlueCrest Capital Management first reported a position in Corcept Therapeutics in Q2 2016 and held it in 1 quarter.
  • BlueCrest Capital Management's Corcept Therapeutics position peaked at $69K in Q2 2016.
  • 110 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2016.

Based on BlueCrest Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.